| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Ben Venue-Bedford Laboratories, Inc. is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.
Aderans Research Institute is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Radiant Research is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.